BCL2 and acute myeloid leukemia: In acute myeloid leukemia, downregulation of SDHB sensitized leukemia cancer cells to BCL-2-inhibitor-induced apoptosis, which may explain the specific anti-tumor effect of the BCL-2 inhibitors towards high OTX2-AS1 expressing cells in medulloblastoma [48].